Breaks Categories: News

ThursdayMar 30, 2017 11:13 am

NetworkNewsBreaks – ChineseInvestors.com, Inc. (CIIX) Invests in Breakwater MB, LLC

Market analysis company ChineseInvestors.com, Inc. (OTCQB: CIIX) this morning announced its investment in Breakwater MB, LLC, a cannabis-focused investment and consulting company formed by CIIX board member and former CFO Paul Dickman. CIIX’s initial investment into Breakwater MB will total $250,000, with the company maintaining an option to make additional investments at its own election. Per the news release, Breakwater MB intends to use the invested capital primarily to cover the costs of becoming a publicly traded company. CIIX management expects that this strategy will provide significant investment appreciate and opportunity for liquidity. “With the gradual opening up of the…

Continue Reading

MondayMar 27, 2017 11:20 am

NetworkNewsBreaks – DryShips, Inc. (NASDAQ: DRYS) Acquires Four Modern Newcastlemax Vessels

DryShips (NASDAQ: DRYS) this morning said that it has entered into agreements with unaffiliated third parties to acquire four modern Newcastlemax bulk carriers of approximately 206,000 DWT and with an average age of 3.0 years. Two of the vessels will be employed under time charter contracts, while the other two will trade in the spot market. DryShips will finance the total gross purchase price of approximately $124 million using cash on hand, and it expects to take delivery of the vessels before the end of June 2017. "We are very pleased to have increased the size of our drybulk fleet by…

Continue Reading

MondayMar 27, 2017 11:19 am

NetworkNewsBreaks – Foamix Pharmaceuticals (NASDAQ: FOMX) Shares Sink on Report of Topline Results from Phase 3 Trials for FMX101

Shares of Foamix Pharmaceuticals (NASDAQ: FOMX) dove 50% this morning following the company’s report of topline results from its two phase 3 clinical trials investigating FMX101 (Trial 04 and Trial 05) in patients with moderate-to-severe acne. The two co-primary endpoints were the absolute change in the number of inflammatory lesions (papules and pustules); and the proportion of patients achieving success at week 12, as defined by an Investigator's Global Assessment (IGA) score of "clear" or "almost clear" and at least a two-grade improvement from baseline at week 12. FMX101 did not demonstrate statistical significance of IGA success in Trial 04.…

Continue Reading

MondayMar 27, 2017 9:38 am

NetworkNewsBreaks – eXp World Holdings, Inc. (EXPI) Scheduled to Present at The MicroCap Conference on April 4

eXp World Holdings, Inc. (OTCQB: EXPI), holding company for the Agent-Owned Cloud Brokerage®, this morning announced that its management team will be attending The MicroCap Conference in New York on Tuesday, April 4, 2017. The company is scheduled to present at 9:30 a.m. ET at the JW Marriott Essex House New York, which is located adjacent to Central Park in Manhattan. The EXPI team will also host one-on-one meetings with prospective investors throughout the day. A webcast of the company’s presentation will be made available at http://wsw.com/webcast/microcapconf3/expi for those who are unable to attend the event. For more information about…

Continue Reading

FridayMar 24, 2017 11:25 am

NetworkNewsBreaks – R-Three Technologies, Inc. (RRRT) Suspends Operations; Triggers Sell-off

R-Three Technologies (OTC: RRRT) shares are down more than 80% mid-morning after the company announced the temporary suspension of its operations. The suspension is pending funding, in either debt or equity financing, to implement the company's business plan. The business plan is to produce a variety of products, such as interlocking asphalt bricks, using recycled asphalt shingles. "The company is attempting to secure a minimum of $200,000 in debt or equity financing. If we secure such level of funding, the Company will be in a position to continue to lay the foundation to implement our business plan. An additional $800,000…

Continue Reading

FridayMar 24, 2017 11:18 am

NetworkNewsBreaks – Xenon Pharmaceuticals, Inc. (NASDAQ: XENE) Shares Dive; XEN801 Disappoints in Phase 2 Clinical Trial

Shares of Xenon Pharmaceuticals (NASDAQ: XENE) are down 51% after the company reported topline efficacy results from the phase 2 clinical trial to evaluate the efficacy, safety, tolerability and systemic exposure of XEN801 for the treatment of moderate to severe facial acne. Trial results show that XEN801 did not demonstrate a statistically significant difference from vehicle placebo in its primary endpoint of the percent change in total lesion count from baseline to week 12. Results also show that XEN801 did not demonstrate statistical significance relative to key secondary efficacy endpoints. “Despite the good scientific and preclinical rationale to pursue SCD1…

Continue Reading

ThursdayMar 23, 2017 2:52 pm

NetworkNewsBreaks – MGX Minerals, Inc. (MGXMF) Enters Agreement to Acquire Working Interest in Paradox Basin

Diversified mining company MGX Minerals, Inc. (OTC: MGXMF) today announced its entry into a joint operating agreement with a private vendor to act as operator and acquire a 75 percent working interest in certain underlying oil and gas leases located contiguous to MGX’s Lisbon Valley petrolithium project. The agreement calls for payments totaling $2 million due on or before September 1, 2018. An accelerated payment schedule reflecting discounted payments is also outlined in the agreement terms. Per the news release, the related leases cover portions of San Juan County, Utah, and San Miguel County, Colorado, including access to the brine-bearing…

Continue Reading

ThursdayMar 23, 2017 1:41 pm

NetworkNewsBreaks – ProBility Media Corp. (PBYA) Reports Record Sales for Fiscal Quarter Ended January 31, 2017

Education technology company ProBility Media Corp. (OTCQB: PBYA) today announced its filing of Form 10-Q for its fiscal first quarter ended January 31, 2017. Notably, the company achieved its third consecutive quarter of year-over-year revenue growth, reporting a 13 percent year-over-year increase to $1 million for the three-month period. “We would like to congratulate and thank the ProBility team for continuing to hit record sales, in addition to many other extraordinary accomplishments achieved over the last year,” Evan Levine, Noah Davis and Steven Plumb, executive management of ProBility Media, noted in a joint statement in the news release. “Through enthusiastic…

Continue Reading

ThursdayMar 23, 2017 12:57 pm

NetworkNewsBreaks – Atossa Genetics, Inc. (NASDAQ: ATOS) Opens Enrollment in Study of Endoxifen; Shares Down

Shares of Atossa Genetics (NASDAQ: ATOS) are 10% lower after the company this morning said that it has opened enrollment of a phase 1 study of endoxifen. Endoxifen is an active metabolite of tamoxifen, an FDA-approved drug for breast cancer. The phase 1 study is a placebo-controlled, repeat dose study of 48 healthy female volunteers. The objective is to assess the pharmacokinetics of proprietary formulations of both oral and topical endoxifen dosage forms over 28 days, as well as to assess safety and tolerability. To view the full press release, visit: http://nnw.fm/1Z9Fg About Atossa Genetics Atossa Genetics Inc., is a…

Continue Reading

ThursdayMar 23, 2017 9:38 am

NetworkNewsBreaks – India Globalization Capital, Inc. (NYSE: IGC) CEO Featured in Audio Interview with NetworkNewsWire

Multifaceted financial news and publishing company NetworkNewsWire this morning announced the online availability of a new audio interview with India Globalization Capital, Inc. (NYSE MKT: IGC) CEO Ram Mukunda. In the interview, Mukunda discusses IGC’s operations and targeted market, as well as leading formulations currently in the company’s development pipeline. “This is a very exciting time for us, an exciting opportunity,” Mukunda noted in the interview. “We believe that we have first-mover advantage in combination therapy, as very few companies are actually working on cannabis-based pharmaceuticals and within that space we believe that we are the only ones working on…

Continue Reading